Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA?) with erlotinib 150 mg (Tarceva?) in Previously Treated Patients with Locally Advanced or Metastatic (Stage III or IV) Non-Small Cell Lung Cancer with High Epidermal Growth Factor Receptor Gene Copy Number (EGFR FISH +)

Next Previous
Trial Profile

A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA?) with erlotinib 150 mg (Tarceva?) in Previously Treated Patients with Locally Advanced or Metastatic (Stage III or IV) Non-Small Cell Lung Cancer with High Epidermal Growth Factor Receptor Gene Copy Number (EGFR FISH +)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ITEM
  • Sponsors AstraZeneca AB

Most Recent Events

  • 03 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top